Wednesday, 15 January 2014

Analytical Tool - Lung Cancer

Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2013".

According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.

This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.

Find out more about each product by clicking on respective links.

This software application is a searchable database reflects the most recent advances in the field of lung cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeekers software applications give better overview, specific search capabilities and great dynamic reports.

To order this report:

Analytical Tool - Lung Cancer

Email: support@researchonglobalmarkets.com
US:  +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE:  Researchonglobalmarkets.com



RELATED VIDEO

Therapeutic Class Report Overview : Hepatitis C Virus Infection

The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future.

Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, Bristol-Myers Squibb (BMY) acquired Inhibitex for $2.5b, VRTX acquired Virochem in 2009 for $375m + in-licensed Alios VX-135 in 2012 for total of $775m, and Abbott in-licensed Enantas ABT-450 for total of $310m. In the next spurt of M&A in this sector, we expect companies which offer differentiated MOA to be in the limelight, are (i) Alleviate the need for Ribavarin, (ii) Address resistance, non-responders, Liver cirrhosis, HIV-HCV -co infection etc, (iii) Target other genotypes, and (iv) Vaccines or Boosters of immune system (toll like receptors). In this report, we have analyzed the novel pipeline candidates, which target unmet needs, offer promise of an all oral IFN-free treatment with at par or better efficacy / compliance, and novel vaccine candidates.

Table of Contents.

1.      Executive Summary

2.      Progress in the Clinical Development of HCV drugs
·       Noteworthy progress in the Oral IFN -Free combinations for Treatment of HCV
·       Options for the most Challenging Patient Subtypes in HCV
·       IFN intolerant and other Genotypes
·       Hepatitis C Virus Prevalence in ROW 

3.      Competitive Landscape - IFN-Free drugs
·       Gilead: Sofosbuvir/GS-5885
·       Abbott: ABT-450r/ABT-472/ABT-333
·       Boehringer Ingelheim: Faldaprevir/BI 207127
·       Medevir: Simeprevir
·       Vertexs VX-135
·       Bristol-Myers: Daclatasvir/Asunaprevir
·       Merck: MK-5172/MK-8742

4.      Market Dynamics- Present and Future
·         Present- Launch of Protease Inhibitors: Sunset Sooner Than Expected.
·         Future- the Best-in-Class IFN-Free Oral Pill for HCV

5.      HCV Vaccines
·         GlobeImmune
·         Okairos
·         ChronTech Pharma/ Inovio
·         Transgenes TG4040
·         Profectus Biosciences HCV vaccine
·         Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

6.      HCV-HIV Co-infection
·         Effects of co-infection
·         Companies targeti ng HIV-HCV Co-infection

7.      ANNEXURE
·         Figures - Designs of ongoing IFN-free PhIII trials
·         Table - Data from IFN-free combinations
·         Table - Viral response in genotype-1 patients - IFN-combinations
·         Key Abstract presented at AASLD 12

To order this report: 


Email: support@researchonglobalmarkets.com
US:  +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600

Related Video


Tuesday, 14 January 2014

Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors

Targeting kinases have been on the agenda of most drug developers/ researchers as they hold the key path to signaling, development and growth of the cell. Tumors/cancer biology indicates that this balance is disturbed and inhibiting the aberrant pathways in a balanced way is an approach to developing drugs against cancer. Resistance to existing therapies develops as cancer cells bypass these efforts and their remains an evergreen search for new targets to meet these challenges. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years.

This report (ToC attached) highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors (PCYC, INFI, CRIS, SymBio, GILD), the clinical data and competition.

KEY POINTS DISCUSSED IN THE REPORT

Drugs in the pipeline

* PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)

* Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)

* BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)

* M&A in Kinase Inhibitors in the last 5 years

* Related Milestones/catalysts in 2013-14

* Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.

* Ongoing Clinical Trials of Companies Covered

Detailed Reports on – 

* Curis (CRIS) - Time to Assess Value Beyond Erivedge!

* Gilead (GILD) - New HIV + HCV Products to Sustain the Growth Trajectory

* Infinity pharma (INFI) - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity! 

* Pharmacyclics (PCYC) - Ibrutinib - Promising to Deliver More

* SymBio (4582) - Significant Upside still Remains: Bendamustine + Rigosertib + Cash to In-license More!

To order this report:

Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors

Email: support@researchonglobalmarkets.com
US:  +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE:  Researchonglobalmarkets.com

Related Video:


Sunday, 12 January 2014

Market Research Reports on Treating Refractory Hematological Malignancies

Market Research Report on Treating Refractory Hematological Malignancies provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.




To Find more :
Visit at : Market Research Reports on Treating Refractory Hematological Malignancies
Mail : support@researchonglobalmarkets.com
Call : +1 866 325 7446 / +91 22 4098 7600

Treating Refractory Hematological Malignancies

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication - Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene are available as a separate or with the full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Table of Contents.

Executive Summary
2. Investment Drivers of The Select Companies Covered
3. Myelodysplastic syndrome (MDS)
3.1 Disease Overview
3.2 Unmet Need
3.3 Current Standard of Care
3.3.1 Supportive Care
3.3.2 Low-Intensity Therapy
3.3.3 High-Intensity Therapy
3.3.4 Recurrent/ Refractory or relapsed MDS
4. Acute Myelogenous Leukemia (AML)
4.1 Disease Overview
4.2 Current Standard of Care
4.2.1 AML pts younger than 60 years
a Induction Therapy
b Post-remission/ consolidation therapy
4.2.2 AML pts Older than 60 years

List Of Figures :

* Ambit Biosciences - MONOTHERAPY RESPONSE RATES (CRc) IN AML

* Ambit Biosciences - QUIZARITINIB - PhIIb COMPARABLE EFFICACY WITH LOWER DOSES 

* Ambit Biosciences - QTC PROLONGATION AT VARIOUS DOSES OF QUIZARTINIB 

* Ambit Biosciences - LONG TERM SURVIVORS IN PHASE 2 - TREATED WITH QUIZARTINIB 

* Ambit Biosciences - QUIZARTINIB MARKET OPPORTUNITY IN US IN AML 

* Ambit Biosciences - OVERALL SURVIVAL FOR AML PTS LESS THAN 60 YEAR OLD WITH FLT3 ITD MUTATION 

* Ambit Biosciences - PROPOSED PHIII TRIAL OF QUIZARTINIB

* Onconova Therapeutics - PHIII TRIAL DESIGN - ONTIME

* Onconova Therapeutics - ITT ANALYSIS: SURVIVAL DATA FOR REFRACTORY MDS PTS

* Onconova Therapeutics - BEST BONE MARROW (BM) RESPONSES AFTER RIG. IV

* Onconova Therapeutics - PHII TRIAL DESIGN - ONTARGET

* Onconova Therapeutics - PHIII TRIAL DESIGN - ONTRAC 

To order this report:

Treating Refractory Hematological Malignancie

Email: support@researchonglobalmarkets.com
US:  +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE:  Researchonglobalmarkets.com

Thursday, 9 January 2014

Market Research Reports on Peptides in Oncology

Research Report on peptides in oncology offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in peptide drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work.




To Find more :
Visit at : Market Research Reports on Peptides in Oncology
Mail : support@researchonglobalmarkets.com
Call : +1 866 325 7446 / +91 22 4098 7600

Market research report on antibodies and peptides in oncology

Antibodies and Peptides in Oncology research report offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work.





To Find more :

Visit at : Market research report on antibodies and peptides in oncology
Mail : support@researchonglobalmarkets.com
Call : +1 866 325 7446 / +91 22 4098 7600